Scientific Programme I Symposia

The theme of ISAD 2019 conference is “Emerging Mood Science and Clinical Innovation”

*Scientific Programme l Symposia is subject to change.

 

Symposium Abstract: S-001  
Date: 14 November 2019 – Thursday
Time:
10:30 – 12:00
Hall:
A
Digital Technology to access and efficiently manage depression and anxiety in primary care and the general community: results of the PReDicT and REBOOT studies. 
Chair: Richard Morriss, University of Nottingham, UK 

Symposium Abstract_1

Digital algorithm used to predict response to antidepressant treatment in the PReDiCT randomised controlled trial
Michael Browning, Department of Psychiatry, University of Oxford, Oxford, United Kingdom

Symposium Abstract_2
The quantitative clinical effectiveness results of the PReDiCT randomised controlled trial
Henricus G. Ruhe, Department of Psychiatry, Radboud University Medical centre, Nijmegen, Netherlands 

Symposium Abstract_3
The acceptability of the PReDiCT algorithm to patients, general practitioners and psychiatrists using both quantitative and qualitative methods
Susan Brown, University of Nottingham, United Kingdom


Symposium Abstract:S-002  
Date: 14 November 2019 – Thursday
Time:
10:30 – 12:00
Hall:
B
Early Life Stress in Affective Disorders: From Neuroscience to Diagnosis and Treatment
Chair: Mario Juruena,King's College London, UK

Symposium Abstract_1

Childhood maltreatment and the physical burden of patients with bipolar disorders. 
Bruno Etain - University Paris Diderot and Assistance Publique des Hopitaux de Paris, Paris, France 

Symposium Abstract_2
Telomere length is associated with childhood trauma experiences in patients with a severe mental disorder. 
Monica Aas– NORMENT K.G Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway 

Symposium Abstract_3
Genetic, HPA axis and early life stress impact in affective disorders.  
Mario F. Juruena - Centre for Affective Disorders, IoPPN, King’s College London, London, UK 

Symposium Abstract_4
Biomarkers for diagnosis and treatment of Bipolar Disorder: New Findings Supporting a Resilience Role for Lithium. 
Rodrigo Machado-Vieira, - Dept. of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, USA 



Symposium Abstract: S-003  
Date: 14 November 2019 – Thursday
Time:
10:30 – 12:00
Hall:
C
Translating evidence from nutritional epidemiology to interventions for depression: challenges, results and future perspectives.

Symposium Abstract_1

An overview of nutritional epidemiology in the context of mental health, highlighting methodological pitfalls and challenges, candidate biological mechanisms and the potential for nutritional and lifestyle strategies in preventing mental disorders.
Michael Berk, Deakin University, IMPACT Strategic Research Centre and the Food & Mood Centre, Victoria, Australia

Symposium Abstract_2
The implementation of the VITAL-DEP trial
Olivia I. Okereke, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, USA

Symposium Abstract_3
The results from the EU-funded MooDFOOD trial.  
Mariska Bot, Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.

Symposium Abstract_4
How recently developed genomic tools could be efficiently employed to examine the nature of observational associations emerging in nutritional epidemiology.
Yuri Milaneschi, Department of Psychiatry, Amsterdam Public Health and Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit/GGZ inGeest, Amsterdam, the Netherlands 


Symposium Abstract: S-004  
Date: 14 November 2019 – Thursday
Time:
14:00 – 15:30
Hall:
A
New platforms and approaches to the prediction of treatment outcomes in major depressive disorder.
Chair: Rudolf Uher, Dalhousie University, Canada

Symposium Abstract_1

Predicting Antidepressant Treatment Outcome in the Canadian Biomarker Integration Network in Depression (CAN-BIND)
Sidney H. Kennedy - St. Michael's Hospital,Toronto, Canada 

Symposium Abstract_2
Combining datasets to identify genetic predictors of response to antidepressants
Oliver Pain, King’s College London, London, UK

Symposium Abstract_3
Integrating published evidence with observational data in real time to support shared decision making for personalised treatment of depression 
Anneka Tomlinson, Department Of Psychiatry, University Of Oxford, United Kingdom

Symposium Abstract_4
Integrative machine learning leverages clinical, neuroimaging and molecular measures to optimize prediction of treatment outcome in major depressive disorder
Rudolf Uher, Dalhousie University, Canada


Symposium Abstract: S-005  
Date: 14 November 2019 – Thursday
Time:
14:00 – 15:30
Hall:
B
Psilocybin Therapy for Treatment Resistant Depression: A Good or Bad Trip?
Chair: James Rucker,Kings College London, United Kingdom.

Symposium Abstract_1
How do Psychedelics Work? A General Overview.
Robin Carhart-Harris, BSc, MSc, PhD. Imperial College London, United Kingdom.

Symposium Abstract_2
Do Psychedelics Cause Long Term Brain Changes?
Taylor Lyons, Imperial College London, United Kingdom.

Symposium Abstract_3
Set and Setting. The Effect of Context in Psilocybin Therapy.

Symposium Abstract_4
Clinical Trials with Psilocybin. What are the Practical Challenges of Delivery?
Aster Daniel, King’s College London, United Kingdom.


Symposium Abstract: S-006  
Date: 14 November 2019 – Thursday
Time:
14:00 – 15:30
Hall:
C
Sleep & Circadian Dysregulation: From Diagnosis to Treatment.
Chair: Bruno Etain, University Paris Diderot, Paris, France.

Symposium Abstract_1
Sleep & Circadian Dysregulation: From Diagnosis to Treatment.
Bruno Etain, University Paris Diderot, Paris, France.

Symposium Abstract_2
Sleep & Circadian Rhythm
Ian Hickie, The University of Sydney, Australia

Symposium Abstract_3
Digital Cognitive Behavior Therapy for Insomnia for individuals with high levels of depressive symptoms: Secondary analyses of a randomized controlled trial.
Havard Kallestad, Ntnu, Trondheim, Norway.


 

Symposium Abstract: S-007  
Date: 15 November 2019 – Friday
Time:
10:30 – 12:00
Hall:
A
The bipolar brain: from risk to treatment, from treatment to aging
Chair: Allan Young, King's College London, UK,

Symposium Abstract_1
Structural magnetic resonance imaging measures as an endophenotype in bipolar disorder
Nefize Yalin, Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry & Psychology and Neuroscience, King’s College of London, London, United Kingdom

Symposium Abstract_2
White matter integrity and brain lithium distribution in bipolar disorder
David Cousins, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom

Symposium Abstract_3
Brain Age in Bipolar Disorders - Effects of Lithium Treatment
Tomas Hajek, Department of Psychiatry, Dalhouise University, Halifax, Canada



Symposium Abstract: S-008  
Date: 15 November 2019 – Friday
Time:
10:30 – 12:00
Hall:
B
Computational Neuroscience Approaches in Mood Disorders
Chair: Henricus Ruhe, Radboudumc/Donders Centre, The Netherlands

Symposium Abstract_1
The necessity and pragmatic applicability of Computational Neuroscience for Clinical Psychiatry
J. D. Steele, University Of Dundee, United Kingdom

Symposium Abstract_2
Challenging the negative learning bias hypothesis of depression: reversal learning in a naturalistic psychiatric sample
Sophie C.A. Brolsma, Radboud University Medical Center, The Netherlands 


Symposium Abstract_3

Impaired reward-related learning signals in remitted unmedicated patients with recurrent depression
Henricus Ruhe, Radboudumc/Donders Centre, The Netherlands

Symposium Abstract_4
How the neuroeconomics revolution will revolutionize psychiatry 
Gregor Hasler, University Of Fribourg, Switzerland



Symposium Abstract: S-009  
Date: 15 November 2019 – Friday
Time:
10:30 – 12:00
Hall:
C
New approaches to understanding the trajectories of mood disorders across the life course.
Chair: Bruno Etain, University Paris Diderot and Assistance Publique des Hopitaux de Paris, France

Symposium Abstract_1
A trajectory analysis of the evolution of familial and non-familial mood disorders and the similarities in illness patterns between parents and probands. 
Jan Scott, Newcastle University, United Kingdom.

Symposium Abstract_2
Delineating the transition from subsyndromal to syndromal disorders and trajectories of social and occupational functioning of young people attending early intervention mental health services in Australia: a longitudinal study.
Ian Hickie, The University of Sydney, Australia.

Symposium Abstract_3
Trajectories and predictors of mood recurrence and functioning in adults in the FACE-BD clinical cohort.
Bruno Etain, Diderot University, Paris, France.

 

 

Symposium Abstract: S-010 
Date: 16 November 2019 – Saturday
Time:
10:00 – 11:30
Hall:
A
Actigraphy research in affective disorders: a global overview from the mMARCH consortium 

Symposium Abstract_1
Joanne S. Carpenter, Brain & Mind Centre, University of Sydney, Camperdown, NSW, Australia.

Symposium Abstract_2
Jennifer Glaus, University Service of Child and Adolescent Psychiatry, Lausanne University Hospital, Lausanne, Switzerland

Symposium Abstract_3

Jihui Zhang, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China;

Symposium Abstract_4
Sonia Difrancesco, Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands 

Symposium Abstract_5
Kathleen R Merikangas, Genetic Epidemiology Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA 


Symposium Abstract: S-011 
Date: 16 November 2019 – Saturday
Time:
10:30 – 12:00
Hall:
B
Pharmacogenetics in unipolar and bipolar depression: review of the latest clinical evidence and new research directions.

Symposium Abstract_1

The evidence supporting pharmacogenetic panels: two steps forward and one step backward, or one step forward and two steps backward?
Simon Kung, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA

Symposium Abstract_2
Is there a role for pharmacogenetics testing in bipolar disorder?
Alfredo B. Cuéllar Barboza, Department of Psychiatry of the Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.

Symposium Abstract_3
Pharmacokinetic-Pharmacodynamics Interaction Associated with Venlafaxine-XR Remission with History of SSRI Treatment Failure
Mark Frye, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA

Symposium Abstract_4
Developing a predictor of treatment-resistant depression: contribution of rare and common genetic variants
Chiara Fabbri, Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London.


Symposium Abstract: S-012 
Date: 16 November 2019 – Saturday
Time:
10:30 – 12:00
Hall:
C
Suicidality in Pediatric Mood Disorders: Implications for Clinical Practice.

Symposium Abstract_1

Do sexual and gender minority adolescents with complex mental health needs have higher rates of depression, anxiety, and suicidality than comparable heterosexual cisgender adolescents? Results from an inpatient psychiatric sample
Ana M. Ugueto,The University of Texas Health Science Center at Houston, McGovern Medical School, Department of Psychiatry and Behavioral Sciences.

Symposium Abstract_2
DMDD and suicidality
Cristian Patrick Zeni, Pediatric Mood Disorders Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, Houston, US.

Symposium Abstract_3
Bipolar Disorder and Suicidality
Iram Kazimi, Pediatric Mood Disorders Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, Houston, US.